Interactions Between Lipoproteins and Platelet Membranes in Obesity

Department of Biochemistry, Biology and Genetics, School of Medicine, Marche Polytechnic University, Ancona, Italy.
Obesity (Impact Factor: 3.73). 03/2009; 17(7):1375-80. DOI: 10.1038/oby.2008.654
Source: PubMed


The aim was to investigate low-density lipoprotein (LDL) composition and Na(+)/K(+) adenosine triphosphatase (ATPase) and Ca(2+) ATPase activities and membrane fluidity measured by 1-(4-trimethylaminophenyl)-6-phenyl-1,3,5-hexatriene (TMA-DPH) in platelets from obese patients and controls in order to identify, if any, platelet membrane's chemical-physical and/or functional modifications associated with compositional modification of circulating lipoproteins. Moreover, we studied the in vitro effect on both platelet transmembrane cationic transport and fluidity, by incubating LDL from 30 obese subjects with platelets from 30 control subjects. The analysis of the chemical composition of LDL from obese patients showed a significant increase in the percent content of total cholesterol (TC) and triglycerides (TGs) and in the mean levels of lipid hydroperoxides compared to controls' LDL. Platelet Na(+)/K(+) ATPase and Ca(2+) ATPase activities showed, respectively, a significant decrease and increase in patients compared to controls; minor significant, respectively, decreases and increases are shown also in control platelets incubated with LDL from obese patients. Anisotropy tested with TMA-DPH probe was significantly increased both in platelets from obese patients and in control platelets incubated with LDL from obese patients compared to control platelets. This study highlights that obesity induces remarkable modifications both in lipoproteins and platelets. Both platelet hyperfunction and quantitative/qualitative alterations in plasma lipoproteins, as well as an altered interaction between circulating lipoproteins and platelets, might play a relevant role in the increased prevalence of the early atherosclerotic lesions development in obese subjects. The present data point out that obesity might represent a major potentially modifiable risk factor for the onset of numerous complications, in particular cardiovascular ones.

Download full-text


Available from: Arianna Vignini, Nov 10, 2014
16 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The proinflammatory and proatherogenic mediator, soluble CD40 ligand (CD40L), is increased in the metabolic syndrome (MS) and released from platelets. We hypothesized that adiponectin modulates platelet function, and we sought to evaluate the association of adiponectin and sCD40L levels with platelet aggregation in MS and the effects of adiponectin on platelet aggregation and activation. Platelet aggregation and circulating adiponectin, sCD40L and P-selectin were determined in 30 controls and 30 patients with MS. Also, in vitro studies were performed in platelet-rich plasma from nine healthy volunteers. Adiponectin receptors were demonstrated by Western blotting and flow cytometry. ADP and epinephrine platelet aggregation was measured after preincubation with adiponectin. sCD40L and P-selectin secretion was measured in the supernatants by ELISA. Patients with MS had higher sCD40L and P-selectin than controls (5.96 +/- 0.50 vs. 4.28 +/- 0.41 ng/ml, P < 0.05, and 151 +/- 8 vs. 122 +/- 9 ng/ml, P < 0.05). By contrast, adiponectin was lower in patients with MS than in controls (5.25 +/- 0.30 vs. 7.35 +/- 0.34 microg/ml, P < 0.001). Higher platelet aggregation was found in MS. Adiponectin inversely correlated with P-selectin (R = -0.35, P = 0.009), sCD40L (r = -0.24, P = 0.05) and epinephrine and collagen induced aggregation (r = -0.80, P = 0.005; r = -0.70, P = 0.011). Platelets express the receptors for adiponectin. Platelet aggregatory response to epinephrine and ADP significantly decreased following preincubation with adiponectin (96 +/- 4 vs. 23 +/- 3%, P < 0.001, and 102 +/- 9 vs. 85 +/- 9%, P = 0.004). Adiponectin prevented platelet sCD40L release (1.63 +/- 0.15 vs. 2.04 +/- 0.20 ng/ml, P < 0.001). Enhanced platelet aggregation and activation markers are found in MS associated with low adiponectin concentrations. Novel evidence is provided demonstrating that adiponectin has antithrombotic properties, since it inhibits platelet aggregation and platelet activation.
    AJP Endocrinology and Metabolism 03/2010; 298(5):E1072-7. DOI:10.1152/ajpendo.00728.2009 · 3.79 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Evidence suggests that serum brain-derived neurotrophic factor (serum BDNF) can be affected by cardiorespiratory fitness (CRF), but this relationship is far from clear. Recent reports show an inverse relationship between serum BDNF and CRF in healthy individuals, and other studies suggest a possible association between serum BDNF and cardiovascular disease. However, the possible interaction between serum BDNF, CRF, and cardiovascular disease risk has not been studied. The purpose of this study was to examine the association among serum BDNF, CRF, and cardiovascular disease risk factors in healthy men. The investigation involved a large sample of men (n = 995, age range: 20-76 years) who live in the central area of South Korea and were recruited into the Preventive Health Study. Our study showed a significant inverse relationship between serum BDNF and relative VO(2)max (r = -0.412, p < 0.0001) and heart rate reserve (r = -0.194, p < 0.0001). Serum BDNF was positively correlated with body mass index (r = 0.80, p < 0.0001), total cholesterol (r = 0.185, p < 0.0001), and triglyceride (r = 0.320, p < 0.0001). Our data suggest that serum BDNF may be associated with effects of increased CRF on cardiovascular disease. However, more research is clearly needed before a determination of whether, and to what extent, serum BDNF may be responsible for some of the health benefits associated with CRF.
    Arbeitsphysiologie 09/2010; 111(2):303-11. DOI:10.1007/s00421-010-1658-5 · 2.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ObjectiveNitric oxide (NO) is a short-lived gaseous messenger with multiple physiological functions including regulation of blood flow, platelet adhesion and aggregation inhibition. NO synthases (NOS) catalyze the conversion of cationic amino acid l-arginine in l-citrulline and NO. Despite an increasing prevalence of obesity and metabolic syndrome (MetS) in the last decades, the exact mechanisms involved in the pathogenesis and cardiovascular complications are not fully understood. We have examined the effects of obesity and MetS on the l-arginine–NO–cGMP pathway in platelets from a population of adolescents.MaterialsA total of twenty six adolescent patients (13 with obesity and 13 with MetS) and healthy volunteers (n = 14) participated in this study. Transport of l-arginine, NO synthase (NOS) activity and cGMP content in platelets were analyzed. Moreover, platelet function, plasma levels of l-arginine, metabolic and clinical markers were investigated in these patients and controls.Resultsl-arginine transport (pmol/109 cells/min) in platelets via system y+L was diminished in obese subjects (20.8 ± 4.7, n = 10) and MetS patients (18.4 ± 3.8, n = 10) compared to controls (52.3 ± 14.8, n = 10). The y+L transport system correlated negatively to insulin levels and Homeostasis Model Assessment of Insulin Resistance (HOMA IR) index. No differences in NOS activity and cGMP content were found among the groups. Moreover, plasma levels of l-arginine were not affected by obesity or MetS.DiscussionOur study provides the first evidence that obesity and MetS lead to a dysfunction of l-arginine influx, which negatively correlates to insulin resistance. These findings could be a premature marker of future cardiovascular complications during adulthood.
    Blood Cells Molecules and Diseases 11/2010; 45(4-45):338-342. DOI:10.1016/j.bcmd.2010.10.003 · 2.65 Impact Factor
Show more